Literature DB >> 23125895

Diagnosis and management of Barrett's metaplasia: What's new.

Fábio Segal1, Helenice Pankowski Breyer.   

Abstract

Barrett's esophagus (BE) is a complication of gastroesophageal reflux disease, and a premalignant lesion for esophageal adenocarcinoma (EAC). Observational studies suggest that endoscopic surveillance is associated with the detection of dysplasia and EAC at an early stage along with improved survival, but controversies still remain. The management of patients with BE involves endoscopic surveillance, preventive and clinical measures for cancer, and endoscopic and surgical approaches to treatment. Deciding upon the most appropriate treatment is a challenge. This study presents the results and the effectiveness of these practices.

Entities:  

Keywords:  Barrett’s esophagus; Esophageal adenocarcinoma; Esophageal premalignancy; Intestinal metaplasia; Metaplastic columnar mucosa

Year:  2012        PMID: 23125895      PMCID: PMC3487185          DOI: 10.4253/wjge.v4.i9.379

Source DB:  PubMed          Journal:  World J Gastrointest Endosc


  66 in total

1.  Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus.

Authors:  P Sharma; A P Weston; M Topalovski; R Cherian; A Bhattacharyya; R E Sampliner
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus.

Authors:  M Guelrud; I Herrera; H Essenfeld; J Castro
Journal:  Gastrointest Endosc       Date:  2001-05       Impact factor: 9.427

3.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.

Authors:  Bergein F Overholt; Charles J Lightdale; Kenneth K Wang; Marcia I Canto; Steven Burdick; Roger C Haggitt; Mary P Bronner; Shari L Taylor; Michael G A Grace; Michelle Depot
Journal:  Gastrointest Endosc       Date:  2005-10       Impact factor: 9.427

4.  Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma.

Authors:  P J Veugelers; G A Porter; D L Guernsey; A G Casson
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

Review 5.  The changing epidemiology of esophageal cancer.

Authors:  W J Blot; J K McLaughlin
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

6.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

7.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

8.  Does methylene blue detect intestinal metaplasia in Barrett's esophagus?

Authors:  Helenice Pankowski Breyer; Sérgio Gabriel Silva De Barros; Ismael Maguilnik; Maria Isabel Edelweiss
Journal:  Gastrointest Endosc       Date:  2003-04       Impact factor: 9.427

9.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study.

Authors:  Douglas A Corley; Theodore R Levin; Laurel A Habel; Noel S Weiss; Patricia A Buffler
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

10.  Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus.

Authors:  Hashem B El-Serag; Thomas V Aguirre; Stephanie Davis; Mark Kuebeler; Achyut Bhattacharyya; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.